Cedazuridine is a cytidine deaminase inhibitor approved in combination with decitabine for the treatment of myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia. It enhances the efficacy of the combination therapy by inhibiting cytidine deaminase, thereby increasing the half-life of decitabine and offering superior therapeutic outcomes compared to decitabine monotherapy. Cedazuridine has been approved by the US FDA for the treatment of specific types of cancer.